Xencor Inc. (NASDAQ:XNCR)’s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $25.57 and last traded at $24.84, with a volume of 146,292 shares. The stock had previously closed at $24.88.

A number of research firms have recently commented on XNCR. Canaccord Genuity set a $27.00 price objective on Xencor and gave the stock a “buy” rating in a research note on Monday, September 12th. Wedbush reiterated an “outperform” rating and issued a $27.00 price objective on shares of Xencor in a research note on Monday, September 12th. Zacks Investment Research lowered Xencor from a “buy” rating to a “hold” rating in a research note on Wednesday, August 31st. Finally, Leerink Swann reiterated an “outperform” rating and issued a $18.00 price objective on shares of Xencor in a research note on Wednesday, June 29th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $23.50.

The stock has a market cap of $1.01 billion, a PE ratio of 26.18 and a beta of 2.14. The stock’s 50-day moving average is $21.73 and its 200 day moving average is $16.24.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/xencor-inc-xncr-sets-new-52-week-high-at-25-57.html

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $1.13 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $1.31. Xencor had a net margin of 39.07% and a return on equity of 22.53%. The company earned $66 million during the quarter, compared to the consensus estimate of $7.43 million. Equities research analysts anticipate that Xencor Inc. will post $0.72 EPS for the current fiscal year.

In other news, VP John R. Desjarlais sold 5,905 shares of the stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $20.00, for a total transaction of $118,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Edgardo Baracchini, Jr. sold 10,000 shares of the stock in a transaction dated Friday, September 2nd. The stock was sold at an average price of $21.06, for a total transaction of $210,600.00. Following the transaction, the insider now owns 10,000 shares of the company’s stock, valued at $210,600. The disclosure for this sale can be found here. Insiders own 4.03% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Deerfield Management Co. increased its position in Xencor by 175.9% in the first quarter. Deerfield Management Co. now owns 3,467,512 shares of the biopharmaceutical company’s stock worth $46,534,000 after buying an additional 2,210,900 shares in the last quarter. Rhenman & Partners Asset Management AB increased its position in Xencor by 10.3% in the first quarter. Rhenman & Partners Asset Management AB now owns 200,000 shares of the biopharmaceutical company’s stock worth $2,684,000 after buying an additional 18,697 shares in the last quarter. Acrospire Investment Management LLC increased its position in Xencor by 8.5% in the second quarter. Acrospire Investment Management LLC now owns 6,347 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 495 shares in the last quarter. Geode Capital Management LLC increased its position in Xencor by 6.2% in the first quarter. Geode Capital Management LLC now owns 216,860 shares of the biopharmaceutical company’s stock worth $2,910,000 after buying an additional 12,622 shares in the last quarter. Finally, UBS Asset Management Americas Inc. increased its position in Xencor by 5.0% in the first quarter. UBS Asset Management Americas Inc. now owns 14,800 shares of the biopharmaceutical company’s stock worth $199,000 after buying an additional 700 shares in the last quarter. Institutional investors own 67.72% of the company’s stock.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

5 Day Chart for NASDAQ:XNCR

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.